EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitLeitlinie

Real life application of the ESMO Guidelines for the prevention and treatment of cancer associated thrombosis: challenges and perspectives

Grigoris Gerotziafas, Elmina Lefkou, Peter Marschang, Matija Kozak, Benilde Cosmi, Agata Stanek

Polish Archives of Internal Medicine · 2025

DOI: 10.20452/pamw.17090 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Polish Archives of Internal Medicine, 2025. Verfasst von Grigoris Gerotziafas und 5 weiteren Autor:innen. Beteiligte Einrichtung: Sorbonne University, INSERM UMR_S_938, Saint-Antoine Research Center, Cancer Biology and Therapeutics Team, Cancer – Angiogenesis – Thrombosis Group,…. Hauptthemen laut MEDLINE: Neoplasms, Thrombosis, Practice Guidelines as Topic. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer‑associated thrombosis (CAT) is the second leading cause of death in cancer patients, significantly affecting their quality of life, survival, and health care costs. This review summarizes key recommendations from the 2023 European Society for Medical Oncology guidelines on CAT prevention and treatment, illustrated by a real‑world case, and examines barriers to their implementation. CAT risk is multifactorial, shaped by tumor‑related factors (type, stage, time since diagnosis), treatment exposures (anticancer agents, surgery, central venous catheters), and comorbidities, captured by the "4TS" rule. Emerging biomarkers (eg, D‑dimer, thrombin generation, coagulome genes) and oncogenic mutations may refine risk stratification. The guidelines recommend routine assessment using models such as the Khorana score, COMPASS‑CAT, or Vienna‑CATS, with COMPASS‑CAT demonstrating superior predictive accuracy for patients with breast, lung, ovarian, or colon cancer. For high‑risk ambulatory patients, thromboprophylaxis is recommended for up to 6 months, with regular reassessment of risk thereafter. Treatment of CAT favors low‑molecular‑weight heparin or oral direct FXa inhibitors (apixaban, edoxaban, rivaroxaban), with incidental venous thromboembolism managed similarly to symptomatic events. The API‑CAT study supports low‑dose apixaban (2.5 mg twice a day) as a safer long‑term treatment. Screening for antiphospholipid antibodies guides therapeutic strategies. Major challenges for optimization of the antithrombotic treatment include renal impairment, thrombocytopenia, and treatment adherence. Oral direct FXa inhibitors may improve quality of life. Effective CAT management requires individualized care, strong clinician-patient communication, and education. The guideline implementation remains suboptimal. Closing the gap demands national strategies promoting health‑provider training, patient empowerment, e‑health applications, equitable access, and dedicated CAT outpatient clinics for sustained, personalized care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsThrombosisPractice Guidelines as TopicHumansEuropeMedical OncologyFemaleAnticoagulantsSocieties, Medical

Substanzen

Anticoagulants

Autor:innen und Institutionen

  • Sorbonne University, INSERM UMR_S_938, Saint-Antoine Research Center, Cancer Biology and Therapeutics Team, Cancer – Angiogenesis – Thrombosis Group, University Institute of Cancerology, Paris, France
  • Thrombosis Center, Tenon – Saint Antoine University Hospital, Hôpitaux Universitaires Est Parisien, Assitance Publique Hôpitaix de Paris, Paris, France
  • Center of Translational Research and Education, Department of Pathology and Laboratory Medicine, Loyola University Stritch School of Medicine, Maywood, Chicago, United States
  • VAS-European Independent Foundation in Angiology / Vascular Medicine, Milan, Italy
  • Hematology-Transfusion Medicine Department, Larissa University Hospital, Faculty of Medicine, University of Thessaly, Larissa, Greece
  • Department of Internal Medicine, Central Hospital of Bolzano (SABES-ASDAA), Teaching Hospital of Paracelsus Medical University (PMU), Bolzano, Italy

Zitieren

APA

Gerotziafas, G., Lefkou, E., Marschang, P., Kozak, M., Cosmi, B., & Stanek, A. (2025). Real life application of the ESMO Guidelines for the prevention and treatment of cancer associated thrombosis: challenges and perspectives. Polish Archives of Internal Medicine. https://doi.org/10.20452/pamw.17090

Vancouver

Gerotziafas G, Lefkou E, Marschang P, Kozak M, Cosmi B, Stanek A. Real life application of the ESMO Guidelines for the prevention and treatment of cancer associated thrombosis: challenges and perspectives. Polish Archives of Internal Medicine. 2025. doi:10.20452/pamw.17090

BibTeX
@article{Gerotziafas2025,
  author = {Gerotziafas, Grigoris and Lefkou, Elmina and Marschang, Peter and Kozak, Matija and Cosmi, Benilde and Stanek, Agata},
  title = {Real life application of the ESMO Guidelines for the prevention and treatment of cancer associated thrombosis: challenges and perspectives},
  journal = {Polish Archives of Internal Medicine},
  year = {2025},
  doi = {10.20452/pamw.17090}
}
Kostenlos starten →